JP2026026092A5 - - Google Patents
Info
- Publication number
- JP2026026092A5 JP2026026092A5 JP2025184688A JP2025184688A JP2026026092A5 JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5 JP 2025184688 A JP2025184688 A JP 2025184688A JP 2025184688 A JP2025184688 A JP 2025184688A JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5
- Authority
- JP
- Japan
- Prior art keywords
- cov
- fraction
- glycoprotein
- quillaja saponaria
- saponaria molina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966271P | 2020-01-27 | 2020-01-27 | |
| US62/966,271 | 2020-01-27 | ||
| US202062976858P | 2020-02-14 | 2020-02-14 | |
| US62/976,858 | 2020-02-14 | ||
| US202062983180P | 2020-02-28 | 2020-02-28 | |
| US62/983,180 | 2020-02-28 | ||
| US202063048945P | 2020-07-07 | 2020-07-07 | |
| US63/048,945 | 2020-07-07 | ||
| US202063051706P | 2020-07-14 | 2020-07-14 | |
| US63/051,706 | 2020-07-14 | ||
| US202063054182P | 2020-07-20 | 2020-07-20 | |
| US63/054,182 | 2020-07-20 | ||
| US16/997,001 US10953089B1 (en) | 2020-01-27 | 2020-08-19 | Coronavirus vaccine formulations |
| US16/997,001 | 2020-08-19 | ||
| US202063129392P | 2020-12-22 | 2020-12-22 | |
| US63/129,392 | 2020-12-22 | ||
| PCT/US2021/015220 WO2021154812A1 (en) | 2020-01-27 | 2021-01-27 | Coronavirus vaccine formulations |
| JP2022545141A JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Division JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026026092A JP2026026092A (ja) | 2026-02-16 |
| JP2026026092A5 true JP2026026092A5 (enExample) | 2026-03-10 |
Family
ID=77079351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Active JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
| JP2025184688A Pending JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Active JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12691171B2 (enExample) |
| EP (1) | EP4097123A4 (enExample) |
| JP (2) | JP7792339B2 (enExample) |
| CN (1) | CN115720581A (enExample) |
| AU (1) | AU2021214064A1 (enExample) |
| BR (1) | BR112022014830A2 (enExample) |
| CA (1) | CA3165371A1 (enExample) |
| GB (1) | GB2610070A (enExample) |
| IL (1) | IL295142A (enExample) |
| MX (1) | MX2022009167A (enExample) |
| TW (1) | TW202142555A (enExample) |
| WO (1) | WO2021154812A1 (enExample) |
| ZA (1) | ZA202401922B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| JP2024516309A (ja) * | 2021-05-05 | 2024-04-12 | ノババックス，インコーポレイテッド | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 |
| CN113773372B (zh) * | 2021-08-15 | 2024-08-02 | 北京科兴中维生物技术有限公司 | 重组蛋白及其制备方法和应用 |
| WO2023025287A1 (zh) * | 2021-08-26 | 2023-03-02 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| CN116808189A (zh) * | 2021-10-22 | 2023-09-29 | 江苏瑞科生物技术股份有限公司 | 一种含有佐剂的新型冠状病毒免疫组合物及其应用 |
| WO2023096990A1 (en) * | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20240125935A (ko) * | 2021-11-30 | 2024-08-20 | 노바백스, 인코포레이티드 | 코로나바이러스 백신 제형물 |
| CN114031675B (zh) * | 2022-01-10 | 2022-06-07 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗和组合物 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| EP4709741A1 (en) * | 2023-05-12 | 2026-03-18 | Icosavax, Inc. | Coronavirus spike glycoprotein receptor binding domains and uses thereof |
| US20250109187A1 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ES2039229T3 (es) | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| NL9002314A (nl) | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| CN102021147B (zh) | 2003-03-24 | 2016-08-03 | 港大科桥有限公司 | 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用 |
| CN1237184C (zh) | 2003-06-03 | 2006-01-18 | 中国科学院上海药物研究所 | 抗SARS－CoV药物作用靶标、药物筛选方法及抗SARS药物 |
| EP1668112A4 (en) | 2003-06-20 | 2009-04-29 | Protein Sciences Corp | SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| EP1508615A1 (en) * | 2003-08-18 | 2005-02-23 | Amsterdam Institute of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| EP1882392A4 (en) | 2005-05-10 | 2009-07-01 | Monsanto Technology Llc | GENES AND THEIR USES FOR PLANT IMPROVEMENTS |
| CN101939334B (zh) | 2007-12-17 | 2015-01-14 | 医疗技术研究局 | C型肝炎病毒抗体 |
| ES2987238T3 (es) * | 2008-12-09 | 2024-11-14 | Novavax Inc | Proteínas F del RSV modificadas y métodos de su uso |
| CN102470168A (zh) | 2009-07-10 | 2012-05-23 | 伊斯克诺瓦公司 | 新组合物 |
| RU2403063C1 (ru) | 2009-08-28 | 2010-11-10 | Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") | Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота |
| CA2805741C (en) | 2010-07-23 | 2019-08-13 | Karin Bengtsson Loevgren | Composition including an iscom matrix and ectodomains |
| SG10201602434UA (en) * | 2011-09-30 | 2016-05-30 | Novavax Inc | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| EP2968510B1 (en) | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
| CN103554244B (zh) | 2013-05-09 | 2016-09-07 | 香雪集团(香港)有限公司 | 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法 |
| EP3046579A1 (en) * | 2013-09-19 | 2016-07-27 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| WO2015080973A1 (en) | 2013-11-26 | 2015-06-04 | Baylor College Of Medicine | A novel sars immunogenic composition |
| JP6975709B2 (ja) | 2015-09-02 | 2021-12-01 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化したウイルスクラスｉ融合タンパク質 |
| CN114617959A (zh) * | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| WO2017161151A1 (en) * | 2016-03-16 | 2017-09-21 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2021147025A1 (en) | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2021154763A1 (en) | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| CN111499692B (zh) * | 2020-06-16 | 2020-12-04 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| US11149286B1 (en) | 2020-08-17 | 2021-10-19 | Mayo Foundation For Medical Education And Research | Adenovirus vectors and methods for using adenovirus vectors |
| KR20230054719A (ko) | 2020-08-24 | 2023-04-25 | 사노피 파스퇴르 인크 | Sars-cov-2 감염에 대한 백신 |
| EP4313143A4 (en) | 2021-03-22 | 2025-06-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2024516309A (ja) | 2021-05-05 | 2024-04-12 | ノババックス，インコーポレイテッド | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 |
-
2021
- 2021-01-27 AU AU2021214064A patent/AU2021214064A1/en active Pending
- 2021-01-27 TW TW110103013A patent/TW202142555A/zh unknown
- 2021-01-27 EP EP21747453.5A patent/EP4097123A4/en active Pending
- 2021-01-27 GB GB2212336.8A patent/GB2610070A/en not_active Withdrawn
- 2021-01-27 JP JP2022545141A patent/JP7792339B2/ja active Active
- 2021-01-27 IL IL295142A patent/IL295142A/en unknown
- 2021-01-27 BR BR112022014830A patent/BR112022014830A2/pt unknown
- 2021-01-27 WO PCT/US2021/015220 patent/WO2021154812A1/en not_active Ceased
- 2021-01-27 MX MX2022009167A patent/MX2022009167A/es unknown
- 2021-01-27 CN CN202180021579.8A patent/CN115720581A/zh active Pending
- 2021-01-27 US US17/795,337 patent/US12691171B2/en active Active
- 2021-01-27 CA CA3165371A patent/CA3165371A1/en active Pending
-
2024
- 2024-03-07 ZA ZA2024/01922A patent/ZA202401922B/en unknown
-
2025
- 2025-10-31 JP JP2025184688A patent/JP2026026092A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU765824B2 (en) | Vaccines | |
| JP2023512648A5 (enExample) | ||
| AU766635B2 (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | |
| Almeida et al. | Nasal delivery of vaccines | |
| JP2024511412A5 (enExample) | ||
| GB2610070A (en) | Coronavirus vaccine formulations | |
| JP2019526580A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| US20150064216A1 (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
| JP2003526673A5 (enExample) | ||
| JP2024516309A5 (enExample) | ||
| US20040047882A1 (en) | Adjuvant for vaccines | |
| JP2023527791A5 (enExample) | ||
| CN112439058A (zh) | 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法 | |
| JP7618632B2 (ja) | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 | |
| US20240261392A1 (en) | Compositions and methods to increase coronavirus immune response | |
| WO2023159082A2 (en) | Nanotechnology based intranasal vaccine for covid-19 comprising chitosan | |
| WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
| EP1987840B1 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| AU2023347247A1 (en) | Methods and materials for using adenovirus vectors to immunize mammals | |
| WO2023159081A2 (en) | Nanotechnology based intranasal vaccine for covid-19 | |
| RU2023126867A (ru) | Вакцинные составы против коронавируса | |
| AU2013206335B2 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
| Verges | World Vaccine Congress Europe 2017. Barcelona, Spain-October 10-12, 2017 | |
| ZA200202270B (en) | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines. |